Strategic Advisory Services

I help companies and investors make high-stakes business development decisions with greater clarity and conviction, assessing opportunities through a commercial lens to determine where to play, what to pursue, and what will truly create value.

Offerings:

• Commercial due diligence for investors, boards, and executive teams

• Business development strategy, partnership evaluation, and deal prioritization

• Market opportunity, competitive positioning, and whitespace assessment

• Commercial viability, execution risk, and go-to-market readiness for assets, platforms, and pipeline opportunities

I help companies navigate the “first light” moments between Phase 2 and launch—when the path is ambiguous and the decisions are consequential.

Offerings:

• Indication, patient, and segment prioritization

• Market development in nascent or under-diagnosed diseases (e.g., Alzheimer’s and neurodegenerative diseases

• Go-to-market strategy, positioning, and value narrative

• Competitive and scenario planning frameworks to “see around corners”

For seed to pre-IPO companies, I design and pressure-test the commercial blueprint before headcount and spend scale.

Offerings:

• Assess “commercial readiness” and build pragmatic roadmaps

• Define critical first hires, org design, and operating model

• Clarify roles/responsibilities across clinical, medical, commercial, advocacy and access

• Embed customer, payer, and advocacy perspectives early so the launch lands in the real world

I bridge clinical, medical, and commercial thinking so products are set up for access and adoption, not just approval.

Offerings:

• Evidence strategy aligned to value story, payer needs, and guidelines

• Early access / pricing & reimbursement thinking in complex or evolving policy environments

• Real-world data and outcomes strategy to support uptake and standard-of-care shifts

• Stakeholder mapping: clinicians, payers, systems, advocacy, caregivers, and policy

I help executives and boards zoom out and make disciplined, portfolio-level choices.

Offerings:

• Portfolio and lifecycle strategy for assets in crowded, evolving, or high-risk categories

• Prioritization frameworks for indications, geographies, and evidence investments

• Risk/contingency planning and scenario work for key readouts or competitive events

• “Next chapter” roadmaps: from first launch to platform or franchise

I translate complex science, technology and strategy into narratives that resonate with investors, partners, and boards.

Offerings:

• Refine company narrative, story arc, and “why now”

• Clear articulation of inflection points, risks, and value-creation levers

• Coaching founders and C-suite on how to tell the story with credibility and heart